MX2023014139A - Bcma como un objetivo para anticuerpos de redireccionamiento de celulas t en linfomas de celulas b. - Google Patents

Bcma como un objetivo para anticuerpos de redireccionamiento de celulas t en linfomas de celulas b.

Info

Publication number
MX2023014139A
MX2023014139A MX2023014139A MX2023014139A MX2023014139A MX 2023014139 A MX2023014139 A MX 2023014139A MX 2023014139 A MX2023014139 A MX 2023014139A MX 2023014139 A MX2023014139 A MX 2023014139A MX 2023014139 A MX2023014139 A MX 2023014139A
Authority
MX
Mexico
Prior art keywords
cell
bcma
target
lymphomas
redirecting antibodies
Prior art date
Application number
MX2023014139A
Other languages
English (en)
Spanish (es)
Inventor
Raluca Verona
Iii Homer Adams
Arnon P Kater
Eric Frederik Eldering
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of MX2023014139A publication Critical patent/MX2023014139A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
MX2023014139A 2021-05-28 2022-05-26 Bcma como un objetivo para anticuerpos de redireccionamiento de celulas t en linfomas de celulas b. MX2023014139A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163194470P 2021-05-28 2021-05-28
US202163209694P 2021-06-11 2021-06-11
PCT/EP2022/064362 WO2022248642A1 (en) 2021-05-28 2022-05-26 Bcma as a target for t cell redirecting antibodies in b cell lymphomas

Publications (1)

Publication Number Publication Date
MX2023014139A true MX2023014139A (es) 2023-12-13

Family

ID=82115891

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023014139A MX2023014139A (es) 2021-05-28 2022-05-26 Bcma como un objetivo para anticuerpos de redireccionamiento de celulas t en linfomas de celulas b.

Country Status (10)

Country Link
US (1) US20220411525A1 (cg-RX-API-DMAC7.html)
EP (1) EP4347039A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024519545A (cg-RX-API-DMAC7.html)
KR (1) KR20240014482A (cg-RX-API-DMAC7.html)
CN (1) CN119679935A (cg-RX-API-DMAC7.html)
AU (1) AU2022281104A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023024822A2 (cg-RX-API-DMAC7.html)
CA (1) CA3221399A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023014139A (cg-RX-API-DMAC7.html)
WO (1) WO2022248642A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116249548A (zh) 2020-05-11 2023-06-09 詹森生物科技公司 用于治疗多发性骨髓瘤的方法
EP4426437A4 (en) 2021-11-03 2025-09-17 Janssen Biotech Inc METHODS FOR TREATING CANCER AND ENHANCING THE EFFICACY OF BISPECIFIC BCMAXCD3 ANTIBODIES

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI811023B (zh) 2015-08-17 2023-08-01 美商健生生物科技公司 抗bcma抗體,結合bcma及cd3之雙特異性抗原結合分子及其用途
EP3615068A1 (en) * 2017-04-28 2020-03-04 Novartis AG Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
WO2019220368A1 (en) * 2018-05-16 2019-11-21 Janssen Biotech, Inc. Bcma/cd3 and gprdc5d/cd3 bispecific antibodies for use in cancer therapy
WO2021092060A1 (en) * 2019-11-05 2021-05-14 Engmab Sarl Methods of treatment

Also Published As

Publication number Publication date
BR112023024822A2 (pt) 2024-02-20
WO2022248642A1 (en) 2022-12-01
US20220411525A1 (en) 2022-12-29
CA3221399A1 (en) 2022-12-01
CN119679935A (zh) 2025-03-25
EP4347039A1 (en) 2024-04-10
KR20240014482A (ko) 2024-02-01
JP2024519545A (ja) 2024-05-15
AU2022281104A1 (en) 2024-01-18

Similar Documents

Publication Publication Date Title
MX2024013526A (es) Metodos para tratar canceres y potenciar la eficacia de agentes terapeuticos para el redireccionamiento de celulas t
ECSP056132A (es) Combinaciones para el tratamiento de enfermedades que implican proliferación, migración o apoptosis celulares de células de mieloma, o angiogénesis
CY1124628T1 (el) Συζευγματα αντισωματος-φαρμακου βασει εριβουλινης και μεθοδοι χρησεως
MX2021006134A (es) Anticuerpos humanizados contra c-kit.
EA201500417A1 (ru) Композиции антагонистов pd-1 и способы применения
PH12018500810A1 (en) Antibody agents specific for human cd19 and uses thereof
JOP20200082A1 (ar) علاج متلازمة الكروموسوم إكس الهش باستخدام الكانابيديول
EA201891509A1 (ru) Способы лечения рака
BR112018073920A2 (pt) inibidores de pd-1/pd-l1 para tratamento de câncer".
EP4512480A3 (en) Cancer treatments using combinations of cdk and erk inhibitors
DOP2015000108A (es) Compuestos de pirrolopirimidina como inhibidores de quinasas
BR112016029492A2 (pt) método para tratamento de linfoma não hodgkin
MX2021006347A (es) Metodos de tratamiento de cánceres que sobreexpresan whsc1 mediante la inhibición de setd2.
MX2024002391A (es) Inhibidores de indolina de kif18a.
MX2021009079A (es) Metodos para tratar el mieloma multiple.
MX2020011817A (es) Metodos para tratar el linfoma.
CR20220166A (es) Métodos para usar inmunoconjugados anti-cd79b para tratar linfoma difuso de linfocitos b grandes
MX2024010506A (es) Composiciones y metodos para la reduccion de celulas madre hematopoyeticas enfermas
DOP2013000131A (es) Composiciones y métodos para tratar el cáncer usando un inhibidor de pi3k y un inhibidor de mek
WO2019136157A3 (en) Reducing beta-catenin and ido expression to potentiate immunotherapy
CO6280488A2 (es) Combinacion farmaceutica
BR112023024822A2 (pt) Bcma como alvo para anticorpos de redirecionamento de células t em linfomas de células b
MX376175B (es) Composiciones de grapiprant y metodos para usar las mismas.
MX2021007330A (es) Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia.
DOP2021000215A (es) Tratamiento de la cefalea usando anticuerpo anti-cgrp